NEW YORK (360Dx) – ACEA Biosciences and Memorial Sloan Kettering Cancer Center today announced a collaboration to evaluate whether patient-specific ex vivo cancer immunotherapy assays can predict in vivo efficacy.

The collaborators will assess the assay, which uses cancer patient's malignant pleural effusions. They also will evaluate ACEA's xCelligence Real-Time Cell Analysis platform to monitor destruction of cancer cells by patients' own genetically modified CAR T cells.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.